Business Wire

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

Share

Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with potent dual 5-HT2A and 5-HT7 antagonist activity with broad potential in psychiatric disease. It is the third molecule created utilising Exscientia’s AI-driven drug discovery platform under a collaboration with Sumitomo Pharma, referred to as design as a service or DaaS.

“With three AI-generated development compounds designed for Sumitomo Pharma, plus our own emerging pipeline, we have repeatedly validated our approach and are on track to achieve our vision of encoding and automating pharmaceutical R&D,” said Andrew Hopkins, founder and Chief Executive Officer at Exscientia. “Using AI, we are creating a much more efficient process to design and develop differentiated drug candidates. We believe that all new therapies will be designed with the help of AI in the future.”

Following the successful conclusion of the DaaS partnership for DSP-2342, Sumitomo Pharma holds all further development, commercial and economic rights to the compound. However, Exscientia maintains ownership of or economic rights to all compounds in its portfolio outside of the original Sumitomo Pharma agreement. These include EXS21546, an A2A receptor antagonist, GTAEXS617, a CDK7 inhibitor and EXS4318, a selective PKC-theta inhibitor being evaluated in inflammatory diseases by Bristol Myers Squibb. In addition, two further wholly owned precision oncology development candidates, EXS74539, an LSD1 inhibitor and EXS73565, a MALT1 protease inhibitor, have been announced recently and are currently progressing through IND/CTA-enabling studies.

About Exscientia

Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients. Visit us at www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the performance of Exscientia’s in generative AI platform and the discovery and development of candidate molecules, and the timing and progress of, and data reported from, preclinical studies and clinical trials of Sumitomo Pharma’s and Exscientia’s wholly or partially owned product candidates. Any statement describing Exscientia’s goals, plans, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that macroeconomic conditions and geopolitical events could have on the Company’s business; the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technological developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investor Relations Contact:
Sara Sherman
investors@exscientia.ai

Media Contact:
Oliver Stohlmann
media@exscientia.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alipay Now Supports Users to Link Alipay to Their Apple ID in a One-stop Way Within Its App1.6.2023 12:32:00 EEST | Press release

Alipay today announced to launch a new feature for iPhone customers with the latest version of Alipay app to quickly add Alipay to their Apple ID and complete payment authorization one-stop within the app. Alipay app is the world’s first third-party payment app to launch this new feature to greatly optimize iPhone customers’ shopping experience. Updating to iOS 16.4 and later, iPhone customers can search for “Apple” in the Alipay app to enter the “Apple Zone”, add Alipay to their Apple ID and complete the payment authorization. This feature is available for users who have yet linked Alipay as the Apple ID payment method and only takes 3 steps for users to get ready to pay for apps, games or in-app purchases, or subscribe to iCloud+ and Apple Music. Users can manage their accounts from the “Apple Zone”, including setting monthly payment limits and checking up details of each purchase etc. In fact, the “Apple Zone” has become a go-to place for Apple customers to check out discounts every

Forecasting, Monitoring and KI – Swarm Intelligence for the Energy Transition at EM-Power Europe1.6.2023 12:26:00 EEST | Press release

The energy transition does not just change the energy generation technologies we use, but also requires the power grids to be updated. Today, instead of a dozen large-scale power plants, an enormous swarm of power plants all feed into our grid: Several thousand wind farms and over 2.6 million PV systems have been installed in Germany alone – and there is a steep upward trend. This makes our power generation weather dependent: On windless or cloudy days, the energy supply may not match the demand, leading to bottlenecks – or worse – blackouts. To keep the grid frequency at a stable 50.2 hertz, grid operators need yield forecasts. Artificial intelligence (AI) helps process this highly complex information and integrate it into the energy system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005572/en/ EM-Power Europe Exhibition (Photo: Solar Promotion GmbH) With millions of solar installations, wallboxes and heat pumps,

European 100 Study Reveals: Despite Year-over-Year Improvements, Tremendous Opportunity to Enhance Hiring with AI, Automation and Experience Remains1.6.2023 12:00:00 EEST | Press release

Phenom released the second annual European Edition of its State of Candidate Experience Report, revealing significant improvement in the use of AI over one year and shining a spotlight on enormous opportunities for companies to enhance job seekers’ experiences through intelligence and automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005156/en/ ‘State of Candidate Experience: 2023 Benchmarks Report — European Edition’ reveals, despite year-over-year improvements, tremendous opportunity to enhance hiring with AI, automation and experience remains. The second annual report provides recommendations, including small steps for making big impacts. (Photo: Business Wire) Phenom audited the top 100 European companies of the Global 500 list in three key areas of the talent journey: attraction, engagement and conversion, as well as the use of AI. By viewing their strengths, weaknesses and opportunities for improvement,

In Industry First, PUMA Creates Sustainability Report Podcast Series to Reach Out to Gen-Z1.6.2023 11:00:00 EEST | Press release

Sports company PUMA has created a podcast series to make its 2022 Sustainability Report more accessible and to reach a wider and younger audience. The RE:GEN REPORTS podcast features next-generation thinkers from six countries and distills the content of the report into 10 podcast episodes, of which the first three are available on all major podcast platforms on June 1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230601005537/en/ Sports company PUMA has created a podcast series to make its 2022 Sustainability Report more accessible and to reach a wider and younger audience. (Photo: Business Wire) The RE:GEN REPORTS podcast, as well as the recently announced Voices of a Re:Generation project, comes as a direct result of the feedback PUMA received at last year’s Conference of the People, which the company organized to discuss solutions for some of the fashion industry’s most pressing sustainability challenges with Gen-Z rep

invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines1.6.2023 11:00:00 EEST | Press release

invoX Pharma Limited (“invoX”), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited (“Sino Biopharm”) (HKEX 1177 HK) with an advancing pipeline of innovative products, today announced that it has completed a second tranche of investment in pHion Therapeutics (“pHion”), a next-generation mRNA vaccine company. The transaction supports invoX’s strategy to be a fully integrated biopharmaceutical company and its ongoing commitment to deliver innovative life-saving therapies pHion is developing a pipeline of therapeutic and prophylactic vaccines focussed on oncology and infectious diseases. The company’s proprietary RALA platform can deliver anionic molecules such as mRNA and saRNA in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo, irrespective of size, into nanoparticles that are highly efficient at cellular

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom